SLC5A2 and chronic kidney disease: Screening for CKD with conventional CKD therapy plus SGLT2 inhibitors yielded gains in life expectancy and QALYs compared with the status quo across all age groups, with larger benefits observed if screening every 5 years were initiated immediately (Figure 1).